Bio Green Med files 1,103,338-share resale as dilution reshapes Bio Green Med Solution stock

Published on 10/25/2026 at 00:46 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

The October 23 filing covers 1,103,338 shares and sends sale proceeds to holders. Dilution terms set a November 19 vote for Bio Green Med Solution stock.

Dilution and shareholder dates

Bio Green Med filed a resale registration for 1,103,338 shares on October 23, 2026.
Second-quarter revenue was USD 336,000 and the net loss was USD 405,000 on August 12, 2026.
Shareholders are scheduled to vote on the proposed transaction on November 19, 2026.

BGMS, US23254L8761, Illustration mit AI erstellt.

Bio Green Med Solution (US23254L8761) filed a registration statement for the resale of up to 1,103,338 common shares on October 23, 2026. According to StockTitan, the selling stockholders would receive the proceeds, while Bio Green Med would not receive money from those resales.

Resale filing adds supply risk

The shares came from a private placement completed on June 10, 2026, at USD 0.72 per share for aggregate proceeds of USD 794,403. The registration statement says the shares represent 16.7 percent of common stock outstanding as of October 5, 2026, and may be sold after the registration becomes effective.

The filing also describes the proposed acquisition of Future NRG Sdn. Bhd. for transaction consideration valued at USD 2.0 billion. Existing Bio Green Med stockholders are expected to retain less than 1.0 percent of the combined company after completion, while Future NRG shareholders are expected to hold more than 99.0 percent, subject to approval and other closing conditions.

What does the dilution mean?

The ownership terms make the November vote the key near-term date. The filing says the special meeting will consider the share issuance, an increase in authorized common stock to 3.0 billion shares and a reverse split between 1-for-4 and 1-for-16. Either party may terminate the transaction if it has not closed by December 31, 2026.

Three dates define the setup

On June 10, 2026, Bio Green Med completed the USD 794,403 private placement. On October 8, 2026, the registration statement for the proposed Future NRG combination became effective, according to the filing. On October 23, 2026, the company filed the resale registration covering 1,103,338 shares.

Results add a financial counterpoint

For the second quarter reported on August 12, 2026, Bio Green Med posted revenue of USD 336,000 and a net loss of USD 405,000, compared with revenue of USD 778,000 and a net loss of USD 197,000 in the prior quarter, according to Investing.com. The next scheduled event is the November 19, 2026 special meeting.

Nasdaq price and market value

Bio Green Med was last at USD 0.96 on Nasdaq on October 23, 2026 at 4:00 p.m. ET. Its market capitalization was USD 5.3 million on that date, while the 52-week range was USD 0.57 to USD 2.80. The resale registration and the proposed transaction leave shareholders weighing potential liquidity against substantial dilution.